Higher MCM2 level was resistant to nine drugs or small molecules, such as Trametinib, and sensitive to 27 drugs, such as NPK76-II-72-1, suggesting that MCM2 may be a potential biomarker for drug screening across cancers (Figure 9B). The gene discussed is MCM2; the disease is cancer.